Hot Genes Biology: Joint venture company publicly increases muscle target MSTN nucleic acid drug core patent.

According to Rhejing Biotechnology, recently, Rhejing Biotechnology's affiliated company Beijing Yaojing Gene Technology Co., Ltd. has been quickly granted a patent by the National Intellectual Property Office for "siRNA inhibiting MSTN gene expression and its conjugates and applications." This patent provides a new therapeutic approach for diseases related to the MSTN gene, such as obesity, by offering a siRNA molecule that can inhibit MSTN gene expression.